Vitamin D2 Supplementation May Lower Your Vitamin D3: What the 2026 Meta-Analysis Found

The long-standing position on vitamin D supplementation has been that D3 (cholecalciferol) is more effective than D2 (ergocalciferol) at raising and maintaining blood levels of 25-hydroxyvitamin D — the standard marker of vitamin D status. A systematic review and meta-analysis published in Nutrition Reviews in 2026 by Brown and colleagues at the University of Surrey, John Innes Centre, and Quadram Institute Bioscience adds a sharper finding: vitamin D2 supplementation does not just under-perform D3, it actually reduces circulating 25(OH)D3 — the form your skin makes from sunlight and the form most laboratory assays use as the primary measure of vitamin D status.

This is a meaningful update to the existing guidance — including our Vitamin D Dosage Guide, which already recommends D3 over D2 on potency grounds. The 2026 data make the case stronger: for people taking D2 (most commonly because it was prescribed at a high weekly dose), the supplement may be subtracting from the very pool of vitamin D it was meant to top up.

What the 2026 Meta-Analysis Did

The authors screened 202 articles published between 1975 and 2023, sourced from PubMed. After eligibility review, 20 studies entered the systematic review and 11 were included in the quantitative meta-analysis. The pooled sample comprised 655 participants: 342 receiving vitamin D2 supplementation and 313 controls.

The primary outcome was the change in serum 25(OH)D3 in the D2-supplemented group versus the control group. The result: D2 supplementation was associated with a statistically significant reduction in 25(OH)D3 relative to controls. The direction of effect was consistent across the majority of the included studies, not driven by one or two outliers.

This is consistent with — and quantitatively reinforces — earlier work. A 2024 Advances in Nutrition meta-analysis and a 2021 Nutrients meta-analysis had already shown that D3 raises total 25(OH)D more reliably than D2 and that D2 may shorten the half-life of circulating D3. The 2026 Brown meta-analysis is the most direct pooled estimate to date of the magnitude and consistency of that D2-on-D3 suppressive effect.

Why D2 Would Lower D3

Three mechanisms have been proposed in the biochemistry literature:

• Competition for the 25-hydroxylase enzyme. Both D2 and D3 are activated in the liver by the same enzyme (CYP2R1, the primary 25-hydroxylase). When D2 is the dominant substrate, the enzyme is occupied converting D2, leaving less throughput for D3 activation.
• Competition for vitamin D binding protein (DBP). The protein that carries vitamin D in blood has affinity for both forms, but binding kinetics differ. Elevated 25(OH)D2 may displace 25(OH)D3 from DBP, exposing it to faster catabolism.
• Faster clearance of 25(OH)D3 in the presence of D2. Animal and tracer studies suggest that 25(OH)D3 turnover accelerates when D2 metabolites are elevated, plausibly through induction of 24-hydroxylase (CYP24A1), the catabolic enzyme that inactivates vitamin D metabolites.

The combination of slower activation and faster clearance plausibly accounts for the net reduction in 25(OH)D3 observed across the trials.

Who Is Most Affected — Prescription D2

The largest practical exposure to vitamin D2 in the U.S. is prescription ergocalciferol 50,000 IU capsules, typically dosed once weekly for 8 to 12 weeks for documented vitamin D deficiency. Prescription D2 became standard partly for historical pricing reasons and partly because, at the time, D2 was the only high-dose option pharmaceutically available. The dosing logic predates the more recent comparative evidence.

If a clinician prescribed D2 50,000 IU weekly to correct a low 25(OH)D level, the 2026 meta-analysis suggests two things to discuss at follow-up:

• The total 25(OH)D measured at re-test may understate the true effect because 25(OH)D2 went up but 25(OH)D3 may have gone down — the net total can move in either direction depending on dose, duration, and baseline.
• A modern alternative is high-dose D3 supplementation, available over-the-counter in 5,000 to 50,000 IU strengths. D3 has been shown in multiple meta-analyses to raise total 25(OH)D more efficiently per unit dose and does not appear to suppress endogenous D3.

This is a question to bring to your clinician, not to act on unilaterally. Prescription decisions about repletion of severe deficiency should involve the prescribing provider — particularly if you have malabsorption conditions, take medications that affect vitamin D metabolism (anticonvulsants, glucocorticoids, certain antifungals), or have chronic kidney disease.

Limitations of the 2026 Meta-Analysis

The Brown et al. analysis is the most direct pooled estimate available, but it carries the typical limitations of a meta-analysis of older heterogeneous trials:

• Heterogeneity in dose, frequency, and duration. Included trials used daily, weekly, and monthly D2 regimens at doses ranging from a few hundred IU to bolus doses of 100,000 IU or more. The magnitude of the D2-on-D3 effect likely varies with dose and frequency.
• Variable baseline 25(OH)D status. Effects in deficient versus replete populations may differ — D2's net cost on D3 may matter most when the D3 pool is already low.
• Assay variability. Older studies used a mix of competitive binding, HPLC, and LC-MS/MS methods, which differ in their ability to distinguish 25(OH)D2 from 25(OH)D3. The 2026 analysis attempted to harmonize by extracting 25(OH)D3-specific outcomes where reported.
• Modest sample size. n=655 across 11 trials is informative but not definitive. A larger contemporary RCT comparing equipotent D2 versus D3 with serial 25(OH)D2, 25(OH)D3, and PTH measurements would resolve remaining uncertainty.

Practical Read for Most People

If you supplement vitamin D over the counter, this evidence reinforces the existing recommendation: choose vitamin D3 (cholecalciferol), not D2 (ergocalciferol). D3 is the form your body produces from sunlight, is more efficient per unit dose at raising 25(OH)D, and does not appear to suppress endogenous D3.

If you have been prescribed weekly D2 50,000 IU for documented deficiency, do not stop the prescription unilaterally. Bring the 2026 finding to your follow-up visit and ask whether equivalent-dose D3 — for example, daily 5,000 to 7,000 IU D3 or weekly 50,000 IU D3 — would be a reasonable substitute given the new evidence. Many clinicians have already been switching to D3 for repletion based on prior comparative data; the 2026 meta-analysis adds quantitative weight to that practice.

For ongoing maintenance dosing rather than acute repletion, our Vitamin D Calculator estimates a target supplement dose based on body weight, current blood levels, and sun exposure. The calculator assumes D3 throughout; if you have been using D2, transitioning to an equivalent D3 dose is the practical action item.

What This Does Not Change

• The overall importance of vitamin D status. Roughly 42% of U.S. adults are below the 20 ng/mL deficiency threshold per NHANES data. The Brown finding affects how you supplement, not whether you should.
• Cofactor guidance. Vitamin K2 (MK-7, 100 to 200 mcg) and magnesium (200 to 400 mg) remain relevant cofactors for vitamin D function — covered in detail in our Vitamin D Dosage Guide.
• Sun exposure as a source. Endogenous D3 synthesis from skin UVB exposure is unaffected by supplementation form. If you get meaningful sun in spring through fall, your D3 pool has a natural input that does not depend on what is in your supplement bottle.
• Testing and retesting. Serum 25(OH)D measurement remains the right way to confirm whether your supplementation is working. Ideally, request the breakdown into 25(OH)D2 and 25(OH)D3 specifically if you are using a D2 product or transitioning between forms — most reference labs can provide it on request.

Bottom Line

A 2026 systematic review and meta-analysis of 11 randomized trials (n=655) reports that vitamin D2 supplementation produces a statistically significant reduction in serum 25(OH)D3 — the form your body naturally synthesizes. This strengthens the existing case for vitamin D3 over D2 in over-the-counter supplementation. For people on prescribed weekly D2, the finding is a reasonable basis to discuss switching to an equivalent D3 protocol with your prescribing clinician at the next follow-up. It does not change overall guidance on vitamin D status, cofactors, or testing — only the choice of supplement form. Pair this with our Vitamin D Calculator for a maintenance dose estimate and the Vitamin D Dosage Guide for the full picture on cofactors, testing, and seasonal adjustment.